ALK and lung carcinoma: While the FDA-approved ALK inhibitor crizotinib has been successfully used to target ALK fusions in lung cancer, Phase I clinical studies using crizotinib saw only a modest response in NB patients, and preclinical studies with crizotinib demonstrated reduced sensitivity in a NB model with F1174L-mutated ALK [10,11].